GlaxoSmithKline (GSK1N) Financial Statements
GlaxoSmithKline Financial Overview
GlaxoSmithKline's market cap is currently $1.87T. The company's EPS TTM is $1.08; its P/E ratio is 17.18; and it has a dividend yield of 3.34%. GlaxoSmithKline is estimated to report earnings on February 3, 2027, and the estimated EPS forecast is $7.02. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 32.67B | $ 31.38B | $ 30.33B | $ 29.32B | $ 24.70B |
| Gross Profit | $ 23.70B | $ 21.90B | $ 21.25B | $ 19.46B | $ 16.34B |
| Operating Income | $ 7.17B | $ 5.66B | $ 6.99B | $ 6.68B | $ 5.41B |
| EBITDA | $ 11.88B | $ 6.67B | $ 9.14B | $ 8.63B | $ 6.45B |
| Net Income | $ 5.72B | $ 2.58B | $ 4.93B | $ 14.96B | $ 4.38B |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 3.16B | $ 3.71B | $ 5.69B | $ 7.68B | $ 4.13B |
| Total Assets | $ 61.12B | $ 59.46B | $ 59.01B | $ 60.15B | $ 79.10B |
| Total Debt | $ 17.72B | $ 16.99B | $ 18.02B | $ 20.99B | $ 24.17B |
| Net Debt | $ 14.57B | $ 13.29B | $ 15.08B | $ 17.46B | $ 20.10B |
| Total Liabilities | $ 45.16B | $ 46.38B | $ 46.21B | $ 50.05B | $ 57.76B |
| Stockholders' Equity | $ 16.38B | $ 13.67B | $ 13.35B | $ 10.60B | $ 15.05B |
| Cash Flow | |||||
| Free Cash Flow | $ 5.96B | $ 3.57B | $ 4.42B | $ 5.14B | $ 5.02B |
| Operating Cash Flow | $ 7.30B | $ 6.55B | $ 6.77B | $ 7.40B | $ 7.95B |
| Investing Cash Flow | $ -5.85B | $ -1.23B | $ -1.59B | $ -8.77B | $ -1.78B |
| Financing Cash Flow | $ -1.63B | $ -4.73B | $ -5.64B | $ 823.00M | $ -7.59B |
Currency in GBP